Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Egbert F Smit

Showing results (311-320 of 320) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 320 results.
The New England Journal of Medicine|May 30, 2020
Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K Paik, Enriqueta Felip, Remi Veillon, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided TreatmentLouisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2016
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Rolf A Stahel, Urania Dafni, et al.
Blood|August 18, 2023
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosisAldo A Acosta-Medina, Paul G Kemps, Timo C E Zondag, et al.
The EMBO Journal|January 16, 2019
Long-term expanding human airway organoids for disease modelingNorman Sachs, Angelos Papaspyropoulos, Domenique D Zomer-van Ommen, et al.
Cancer Cell|August 16, 2017
Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated PlateletsMyron G Best, Nik Sol, Sjors G J G In 't Veld, et al.
Cancer Cell|September 2, 2022
Detection and localization of early- and late-stage cancers using platelet RNASjors G J G In 't Veld, Mohammad Arkani, Edward Post, et al.
Pageof 32

Showing results (311-320 of 320) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 320 results.
The New England Journal of Medicine|May 30, 2020
Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsPaul K Paik, Enriqueta Felip, Remi Veillon, et al.
The Lancet. Oncology|August 1, 2024
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trialYi-Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
The Lancet. Respiratory Medicine|March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaborationAnne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided TreatmentLouisa R Hoes, Jade M van Berge Henegouwen, Hanneke van der Wijngaart, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 27, 2016
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung TrialSolange Peters, Rolf A Stahel, Urania Dafni, et al.
Blood|August 18, 2023
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosisAldo A Acosta-Medina, Paul G Kemps, Timo C E Zondag, et al.
The EMBO Journal|January 16, 2019
Long-term expanding human airway organoids for disease modelingNorman Sachs, Angelos Papaspyropoulos, Domenique D Zomer-van Ommen, et al.
Cancer Cell|August 16, 2017
Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated PlateletsMyron G Best, Nik Sol, Sjors G J G In 't Veld, et al.
Cancer Cell|September 2, 2022
Detection and localization of early- and late-stage cancers using platelet RNASjors G J G In 't Veld, Mohammad Arkani, Edward Post, et al.
Pageof 32